By targeting the BRAF V600E mutation and blocking the MAPK/ERK signaling pathway, targeted therapy significantly reduces the proliferation of PCP tumor cells, slowing or even halting disease progression (Fig. 3). Here, MAPK1 is linked to neoplasm.